GlassScriptPhysician profile
Steven P Kalter
NPI 1922032218
$26,910.60
in general payments reported to CMS, 2019-2025
85 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,396 · 2020: $3,706 · 2021: $3,902 · 2022: $4,798 · 2023: $4,934 · 2024: $5,033 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,042 · Education: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,042.27 |
| Education | $1,067.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,250.37 | 2019-2024 | Opdualag, Onureg, Opdivo |
| Astrazeneca Pharmaceuticals LP | $1,837.07 | 2019-2024 | Enhertu, Calquence, Tagrisso |
| Novartis Pharmaceuticals Corporation | $1,753.02 | 2019-2025 | |
| Janssen Biotech, INC. | $1,507.86 | 2019-2024 | Erleada, Darzalex, Akeega |
| Astellas Pharma US INC | $1,289.70 | 2019-2024 | Xospata, Padcev, Xtandi |
| Genzyme Corporation | $1,067.89 | 2019-2024 | |
| Amgen INC. | $1,035.50 | 2019-2023 | Xgeva, Nplate, Kyprolis |
| Incyte Corporation | $1,015.66 | 2019-2024 | Jakafi, Monjuvi |
| Celgene Corporation | $1,001.35 | 2019-2024 | Pomalyst, Reblozyl |
| Seagen INC. | $897.46 | 2019-2024 | Tukysa, Padcev, Adcetris |
| Eisai INC. | $891.18 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $882.99 | 2019-2024 | Vpriv, Alunbrig, Iclusig |
| Genentech USA, INC. | $840.78 | 2019-2024 | Polivy, Lunsumio, Tecentriq |
| Pfizer INC. | $771.15 | 2019-2024 | |
| Daiichi Sankyo INC. | $596.52 | 2019-2024 | Enhertu, Vanflyta, Injectafer |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $544.56 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Karyopharm Therapeutics INC. | $516.99 | 2020-2024 | Xpovio |
| Rigel Pharmaceuticals, INC. | $423.11 | 2019-2024 | Rezlidhia, Tavalisse |
| Regeneron Healthcare Solutions, INC. | $411.00 | 2019-2024 | Libtayo |
| Merck Sharp & Dohme LLC | $381.60 | 2019-2021 | |
| Abbvie INC. | $329.40 | 2019-2025 | |
| Taiho Oncology, INC. | $292.54 | 2019-2024 | |
| Pharmaessentia USA Corporation | $284.18 | 2022-2024 | Besremi |
| Glaxosmithkline, LLC. | $278.89 | 2021-2024 | Ojjaara, Shingrix |
| Puma Biotechnology, INC. | $256.78 | 2020-2024 | |
| Genmab U.S., INC. | $239.20 | 2023-2024 | Epkinly |
| Gilead Sciences, INC. | $235.11 | 2019-2024 | Trodelvy |
| Sobi, INC | $235.03 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $228.46 | 2020-2024 | Ultomiris, Soliris |
| Sanofi-Aventis U.S. LLC | $213.47 | 2020-2024 | |
| Ipsen Biopharmaceuticals, INC | $207.86 | 2019-2024 | Onivyde, Somatuline Depot |
| Emd Serono, INC. | $206.73 | 2019-2023 | Tepmetko, Bavencio |
| Jazz Pharmaceuticals INC. | $206.07 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $198.25 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $184.27 | 2019-2024 | Xarelto |
| Morphosys, US INC. | $182.74 | 2021-2024 | Monjuvi |
| Exelixis INC. | $175.83 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $161.80 | 2019-2021 | |
| Blueprint Medicines Corporation | $159.09 | 2020-2024 | Ayvakit |
| Aveo Pharmaceuticals, INC. | $137.84 | 2021-2024 | Fotivda |
| Pharmacosmos Therapeutics INC. | $132.67 | 2020-2022 | |
| Foundation Medicine, INC. | $126.57 | 2020-2023 | Foundationone Cdx |
| Sumitomo Pharma America, INC. | $121.45 | 2023-2025 | Orgovyx, Gemtesa |
| Beigene USA, INC. | $115.01 | 2020-2024 | Brukinsa |
| Dova Pharmaceuticals | $112.12 | 2019-2021 | |
| Kite Pharma, INC. | $110.48 | 2020-2023 | |
| Servier Pharmaceuticals LLC | $104.45 | 2021-2024 | |
| Apellis Pharmaceuticals, INC. | $98.04 | 2022-2024 | Empaveli |
| Array Biopharma INC | $96.66 | 2019-2024 | Mektovi, Xalkori, Lorbrena |
| Verastem, INC. | $95.78 | 2019 | |
| Cti Biopharma Corp. | $91.98 | 2022-2023 | Vonjo |
| Amag Pharmaceuticals, INC. | $86.81 | 2019-2021 | |
| Spectrum Pharmaceuticals INC. | $85.83 | 2023-2024 | Rolvedon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.25 | 2019-2023 | Gilotrif |
| Mirati Therapeutics, INC. | $81.03 | 2023-2024 | Krazati |
| Epizyme, INC. | $72.64 | 2020-2021 | |
| Stemline Therapeutics INC. | $72.38 | 2023-2024 | Orserdu |
| Myovant Sciences INC. | $70.47 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $65.09 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $57.28 | 2024-2025 | Alymsys, Neupogen, Neulasta |
| Tersera Therapeutics LLC | $57.25 | 2022-2024 | Zoladex |
| Kyowa Kirin, INC. | $55.61 | 2020-2022 | |
| Global Blood Therapeutics, INC. | $49.42 | 2021 | |
| Secura Bio, INC. | $49.22 | 2020-2023 | Copiktra |
| Adaptive Biotechnologies Corporation | $45.99 | 2021-2023 | Clonoseq |
| Fennec Pharmaceuticals, INC. | $43.69 | 2024 | Pedmark |
| Adc Therapeutics America, INC. | $32.20 | 2022-2024 | |
| Agios Pharmaceuticals, INC. | $30.54 | 2023-2024 | Pyrukynd |
| Medtronic USA, INC. | $28.24 | 2019 | |
| Clovis Oncology, INC. | $26.45 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $26.15 | 2020 | |
| Immunomedics, INC. | $25.69 | 2020 | |
| Deciphera Pharmaceuticals INC. | $22.47 | 2023 | Qinlock |
| Coherus Oncology, INC. | $22.21 | 2022 | |
| Macrogenics, INC. | $21.77 | 2022 | |
| Acceleron Pharma, INC. | $20.97 | 2021 | |
| Tolmar, INC. | $20.54 | 2023 | |
| Octapharma USA, INC. | $20.00 | 2024 | Panzyga |
| Helsinn Therapeutics (U.S.), INC. | $18.96 | 2019 | |
| Azurity Pharmaceuticals, INC. | $15.61 | 2024 | Vivimusta |
| Tempus Ai, INC | $14.70 | 2024 | |
| Corium, LLC | $14.36 | 2025 | Azstarys |
| Mylan Institutional INC. | $13.17 | 2020 | |
| Phathom Pharmaceuticals, INC. | $12.95 | 2025 | Voquezna |
| Eusa Pharma (US) LLC | $11.15 | 2020 |
Drugs and devices associated with these payments
Xpovio $362Reblozyl $300Pomalyst $277Enhertu $276Opdualag $267Besremi $260Epkinly $259Jakafi $251Onureg $250Lenvima $231Sarclisa $220Erleada $209Venclexta $203Opdivo $197Calquence $197Libtayo $176Pluvicto $172Doptelet $166Darzalex $156Kisqali $155Verzenio $154Tukysa $152Scemblix $143Ibrance $133Orgovyx $131Jaypirca $122Vpriv $120Akeega $119Rezlidhia $112Tavalisse $112Enjaymo $110Ojjaara $109Stivarga $106Vitrakvi $106Piqray $105Onivyde $102Somatuline Depot $102Xtandi $99.58Krazati $97.45Padcev $97.11Polivy $96.31Lunsumio $96.31Ayvakit $95.90Inqovi $93.38Lonsurf $93.38Fotivda $91.11Monjuvi $90.12Rolvedon $85.83Xospata $83.97Ultomiris $83.96Talzenna $81.12Tecvayli $80.75Adcetris $79.30Orserdu $72.38Vonjo $68.34Retevmo $64.95Fabhalta $64.45Imbruvica $64.34Tecentriq $60.16Gilotrif $57.65Alunbrig $56.06Trodelvy $55.15Cablivi $53.90Tagrisso $53.20Iclusig $51.37Ninlaro $49.68Fruzaqla $47.61Inlyta $47.11Eliquis $45.93Pedmark $43.69Tepmetko $43.16Brukinsa $42.38Balversa $42.21Promacta $40.49Alymsys $38.04Oxbryta $37.00Xgeva $35.31Nplate $35.31Bosulif $35.30Elrexfio $35.30Zoladex $30.84Pyrukynd $30.54Soliris $26.63Columvi $26.52Gazyva $25.84Synagis $25.72Tibsovo $24.83Gemtesa $24.63Xarelto $24.48Vanflyta $24.45Kyprolis $24.30Rybrevant $23.06Qinlock $22.47Alecensa $22.00Lynparza $21.83Injectafer $21.48Eligard $20.54Tasigna $20.37Panzyga $20.00Bavencio $19.62
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.